Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus

Abstract

DAA-based eradication of HCV is associated with improved glycemic control in patients with diabetes as evidenced by decreased mean HbA and decreased insulin use. These endocrine benefits of SVR provide additional justification for considering antiviral treatment in all patients with diabetes.

The Effect of Hepatitis C Virus Eradication with New Direct Acting Antivirals on Glucose Homeostasis in Non-Diabetic Egyptian Patients

“…This is in agreement with several studies [12,[15][16][17]. Abdel Alem et al, found a reduction in both FBS and HbA1c after HCV eradication [18].…”

“…According to our findings, the call for treating hyperglycemia by eradication of HCV should be reevaluated [17].…”

The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C

“…It is evident that there are limited data to adequately answer this question, even if the few studies seem to indicate a clear beneficial effect on the control of metabolic condition. An assessment was made in a study that enrolled a large number of HCV patients with T2DM treated with DAAs by comparing patients with SVR and those who did not [9]. The clearance of HCV by DAAs was associated with a significant improvement in glycemic control and a decrease in the amount of antidiabetic drugs and in particular of the insulin dose used [9].…”

Real‐world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan

“…The HbA1c level fell shortly after LDV/SOF. The results in this study revealed a decline of HbA1c in both DM and non‐DM patients following the SVR, indicating that better sugar control may be a favorable result of successful DAA treatment in CHC patients . However, parameters associated with insulin, insulin resistance, and beta‐cell function remained unchanged in this study.…”